🔗 Share this article

Given that the United States undertakes historic adjustments to its immunization schedules, an unexpected name has emerged in a surprising turn: Høeg, a Danish American physician and public health researcher who rose to prominence by questioning Covid vaccinations throughout the global health crisis and has zeroed in on potential fatalities following COVID-19 immunization in her short time at the FDA.

Proposed Changes to Pediatric Vaccine Schedule

Public health authorities planned to announce major revisions to the pediatric vaccination calendar earlier this month, synchronizing the US with the Danish immunization schedule, sources say – a significant shift that would place the US at odds with a large portion of the world with little proof for improved outcomes. The planned update has been pushed back until the next year.

Instead of the director of the vaccine center, Dr. Høeg is scheduled to present at the event. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the center this calendar year.

Consolidating Power at the Regulatory Body

Høeg's temporary position may indicate a closer partnership between the pharmaceutical and vaccine divisions as Dr. Høeg and Prasad consolidate power at the FDA – and it signals a greater focus upon dismantling already-approved vaccines at the FDA.

Høeg has often pushed for halting certain pediatric vaccine recommendations in the US in order to be more like the Danish model, a society with universal health coverage and a number of inhabitants roughly the size of Wisconsin’s.

So far comments, she has continued to focus on immunizations – traditionally the purview of Dr. Prasad, director of the FDA’s vaccine center – rather than drug regulation.

Concerns Over Qualifications

Dr. Høeg has little discernible track record in medication creation, regulation or management, which has been standard for past directors of the biologics center. She has served at the FDA as a top consultant to the FDA chief and the vaccine center since spring.

“It seems she lacks to have the necessary background” for running the drug-regulation department, said Dr. Jonathan Howard. “She’s never run a scientific study. She lacks experience in running a large organization. She has no expertise in pharmaceutical oversight.”

Previous commissioners of the center would “grasp regulatory frameworks and the science of medication creation”, commented Janet Woodcock. “Objectively, she has not acquired the kind of background that former directors who headed CBER have had.”

This division has an enormous workload at the FDA, she emphasized.

“The public just pays attention on the innovative therapies, but the generic drug division authorizes numerous generic drugs. There’s a biologic copycat branch, non-prescription drug unit and other areas, and every single one need to be looked after,” Woodcock said. “The thing you overlook, that is precisely what that I always told people is going to cause problems.”

Furthermore, a significant administrative component to the role, which manages more than 5,000 employees. “It is a enormous management job, if you do it right,” she said.

Official Statement and Contentious Initiatives

Regarding questions about Høeg’s qualifications and whether this appointment indicates increased cooperation among regulatory chiefs on vaccines, a press secretary responded that the “concerns stem from flawed presumptions”.

“Her resume is consistent with the duties of her role,” the representative said, pointing to the time Dr. Høeg spent counseling the agency head on “pharmaceutical safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Høeg inherits the agency head's new priority voucher program, a contentious rapid drug-approval program that reportedly troubled her former heads. “How are these drugs being chosen for this fast-track system? Who makes the calls?” Howard said. “There is a lot of lack of transparency occurring at the agency right now.”

Broadly speaking, he said, “the agency looks to be trending towards less stringent oversight of all drugs, with the exception of vaccines.”

Established Past Work on Immunizations

Regarding immunizations, Dr. Høeg has a more documented, if concerning, past, critics observe. She released a analysis using non-validated crowd-sourced reports to determine the frequency of heart inflammation following COVID-19 immunization. She advised the state of Florida surgeon general Dr. Joseph Ladapo, who allegedly have modified findings to suggest COVID-19 vaccines are more dangerous than they are.

Part of her “policy goals” for the incoming administration featured revising rules for recently developed shots and halting “unnecessary” immunizations, she said after the election on a podcast. At the agency, Høeg has reportedly proposed preventing young men from receiving COVID-19 vaccines.

“She is an complete ideologue who starts off with her conclusions and works backwards to fit the data in a highly misleading, dishonest manner,” Howard argued.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg became part of other contrarians, {like|